Pathophysiology of oral cancer in experimental animal models: A review with focus on the role of sympathetic nerves

Journal of Oral Pathology and Medicine

Volumn 40, Issue 1, 2011, Pages 1-9

  Raju, Bina ^a   Ibrahim, Salah O ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

4 NQO; Animal model; Interstitial fluid pressure; Oral cancer; Sympathetic nerves

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; ADRENERGIC RECEPTOR; BIOLOGICAL MARKER; CADHERIN; CARCINOGEN; CATECHOLAMINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN D1; CYCLINE; CYTOKERATIN; CYTOKINE; CYTOKINE RECEPTOR; DIMETHYLBENZ[A]ANTHRACENE; DOPA; DOPAMINE; G PROTEIN COUPLED RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; NEUROTRANSMITTER; NEUROTROPHIC FACTOR; NORADRENALIN; PROTEIN KINASE C; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; TYROSINE 3 MONOOXYGENASE; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR;

ADRENERGIC SYSTEM; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD VESSEL PERMEABILITY; BRAIN; CARCINOGENESIS; CHEMICAL CARCINOGENESIS; ENZYME ACTIVATION; EXPERIMENTAL MODEL; FLUID TRANSPORT; GENE EXPRESSION; GROWTH INHIBITION; HEAD AND NECK CANCER; HYPOXIA; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; INNERVATION; INTERSTITIAL FLUID; LYMPHANGIOGENESIS; MICROARRAY ANALYSIS; MOUSE; MOUTH CANCER; NERVE CELL; NEUROIMMUNOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; REVIEW; SUPERIOR CERVICAL GANGLION; SYMPATHECTOMY; SYMPATHETIC NERVE; TUMOR BLOOD FLOW; TUMOR GROWTH;

ANIMALS; CHEMOKINES; DISEASE MODELS, ANIMAL; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MOUTH; MOUTH NEOPLASMS; NEOPLASMS, EXPERIMENTAL; SYMPATHETIC NERVOUS SYSTEM; TUMOR MARKERS, BIOLOGICAL;

EID: 78650779717     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2010.00928.x     Document Type: Review

References (114)

1. Moore SR, Johnson NW, Pierce AM, et al. The epidemiology of tongue cancer: a review of global incidence. Oral Dis 2000; 6: 75-84.
2. Scully C, Bagan J. Oral squamous cell carcinoma overview. Oral Oncol 2009; 45: 301-8.
3. Petersen PE. Strengthening the prevention of oral cancer: the WHO perspective. Commun Dent Oral Epidemiol 2005; 33: 397-9.
4. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol 2000; 36: 256-63.
5. Lewin F, Norell SE, Johansson H, et al. Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer 1998; 82: 1367-75.
6. Scully C. Oral squamous cell carcinoma; from an hypothesis about a virus, to concern about possible sexual transmission. Oral Oncol 2002; 38: 227-34.
7. Thaker PH, Sood AK. Neuroendocrine influences on cancer biology. Semin Cancer Biol 2008; 18: 164-70.
8. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev 2002; 82: 673-700.
9. Salley JJ. Experimental carcinogenesis in the cheek pouch of the Syrian hamster. J Dent Res 1954; 33: 253-62.
10. Vered M, Yarom N, Dayan D. 4NQO oral carcinogenesis: animal models, molecular markers and future expectations. Oral Oncol 2005; 41: 337-9.
11. Wallenius K, Lekholm U. Oral cancer in rats induced by the water-soluble carcinogen 4-nitrochinoline N-oxide. Odontol Revy 1973; 24: 39-48.
12. Ohne M, Satoh T, Yamada S, et al. Experimental tongue carcinoma of rats induced by oral administration of 4-nitroquinoline 1-oxide (4NQO) in drinking water. Oral Surg Oral Med Oral Pathol 1985; 59: 600-7.
13. Nakahara W, Fukuoka F, Sugimura T. Carcinogenic action of 4-nitroquinoline-N-oxide. Gan 1957; 48: 129-37.
14. Tanuma J, Hirano M, Hirayama Y, et al. Genetic predisposition to 4NQO-induced tongue carcinogenesis in the rat. Med Princ Pract 2005; 14: 297-305.
15. Kanojia D, Vaidya MM. 4-Nitroquinoline-1-oxide induced experimental oral carcinogenesis. Oral Oncol 2006; 42: 655-67.
16. RUNDLE A. Carcinogen-DNA adducts as a biomarker for cancer risk. Mutat Res 2006; 600: 23-36.
17. Kawazoe Y, Tamura M, Araki M. Metabolism of carcinogenic 4-hydroxyaminoquinoline 1-oxide in mice. Gann 1970; 61: 593-6.
18. Sugimura T, Okabe K, Nagao M. The metabolism of 4-nitroquinoline-1-oxide, a carcinogen. 3. An enzyme catalyzing the conversion of 4-nitroquinoline-1-oxide to 4-hydroxyaminoquinoline-1-oxide in rat liver and hepatomas. Cancer Res 1966; 26: 1717-21.
19. Bailleul B, Daubersies P, Galiegue-Zouitina S, et al. Molecular basis of 4-nitroquinoline 1-oxide carcinogenesis. Jpn J Cancer Res 1989; 80: 691-7.
20. Tang XH, Knudsen B, Bemis D, et al. Oral cavity and esophageal carcinogenesis modeled in carcinogen-treated mice. Clin Cancer Res 2004; 10: 301-13.
21. Nauta JM, Roodenburg JL, Nikkels PG, et al. Comparison of epithelial dysplasia - the 4NQO rat palate model and human oral mucosa. Int J Oral Maxillofac Surg 1995; 24: 53-8.
22. Starling EH. On the absorption of fluids from the connective tissue spaces. J Physiol 1896; 19: 312-26.
23. Aukland K, Reed RK. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev 1993; 73: 1-78.
24. Raju B, Haug SR, Ibrahim SO, et al. High interstitial fluid pressure in rat tongue cancer is related to increased lymph vessel area, tumor size, invasiveness and decreased body weight. J Oral Pathol Med 2008; 37: 137-44.
25. Heldin CH, Rubin K, Pietras K, et al. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004; 4: 806-13.
26. Lunt SJ, Kalliomaki TM, Brown A, et al. Interstitial fluid pressure, vascularity and metastasis in ectopic, orthotopic and spontaneous tumours. BMC Cancer 2008; 8: 2.
27. Sarntinoranont M, Rooney F, Ferrari M. Interstitial stress and fluid pressure within a growing tumor. Ann Biomed Eng 2003; 31: 327-35.
28. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-80.
29. Sullivan R, Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 2007; 26: 319-31.
30. Boucher Y, Lee I, Jain RK. Lack of general correlation between interstitial fluid pressure and oxygen partial pressure in solid tumors. Microvasc Res 1995; 50: 175-82.
31. Ji RC. Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: new insights into intratumoral and peritumoral lymphatics. Cancer Metastasis Rev 2006; 25: 677-94.
32. Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin Exp Metastasis 2008; 26: 19-34.
33. Hofmann M, Guschel M, Bernd A, et al. Lowering of tumor interstitial fluid pressure reduces tumor cell proliferation in a xenograft tumor model. Neoplasia 2006; 8: 89-95.
34. Karpanen T, Alitalo K. Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol 2008; 3: 367-97.
35. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002; 1: 219-27.
36. Ali MA. Lymphatic microvessel density and the expression of lymphangiogenic factors in oral squamous cell carcinoma. Med Princ Pract 2008; 17: 486-92.
37. Chuang WY, Yeh CJ, Wu YC, et al. Tumor cell expression of podoplanin correlates with nodal metastasis in esophageal squamous cell carcinoma. Histol Histopathol 2009; 24: 1021-7.
38. Fukumura D, Jain RK. Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize. J Cell Biochem 2007; 101: 937-49.
39. Jain RK, Fenton BT. Intratumoral lymphatic vessels: a case of mistaken identity or malfunction? J Natl Cancer Inst 2002; 94: 417-21.
40. Leu AJ, Berk DA, Lymboussaki A, et al. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 2000; 60: 4324-7.
41. Fleischer AC. Sonographic depiction of tumor vascularity and flow: from in vivo models to clinical applications. J Ultrasound Med 2000; 19: 55-61.
42. Masaki T, Ohkawa S, Amano A, et al. Noninvasive assessment of tumor vascularity by contrast-enhanced ultrasonography and the prognosis of patients with nonresectable pancreatic carcinoma. Cancer 2005; 103: 1026-35.
43. Liu C, Liang P, Wang Y, et al. Assessment of hepatic VX(2) tumors with combined percutaneous transhepatic lymphosonography and contrast-enhanced ultrasonographic imaging. World J Gastroenterol 2008; 14: 3908-13.
44. Kaplan I, Hochstadt T, Dayan D. PCNA in palate and tongue mucosal dysplastic lesions induced by topically applied 4NQO in desalivated rat. Med Oral 2002; 7: 336-43.
45. Sakaki T, Tamura I, Kadota H, et al. Changing expression of E- and P-cadherin during rat tongue carcinogenesis induced by 4-nitroquinoline 1-oxide. J Oral Pathol Med 2003; 32: 530-7.
46. Bian Y, Terse A, Du J, et al. Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res 2009; 69: 5918-26.
47. Czerninski R, Amornphimoltham P, Patel V, et al. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res (Phila Pa) 2009; 2: 27-36.
48. Szallasi Z. Bioinformatics. Gene expression patterns and cancer. Nat Biotechnol 1998; 16: 1292-3.
49. Chen C, Mendez E, Houck J, et al. Gene expression profiling identifies genes predictive of oral squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2008; 17: 2152-62.
50. Choi P, Jordan CD, Mendez E, et al. Examination of oral cancer biomarkers by tissue microarray analysis. Arch Otolaryngol Head Neck Surg 2008; 134: 539-46.
51. Estilo CL, O-Charoenrat P, Talbot S., et al. Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC Cancer 2009; 9: 11.
52. Tomioka H, Morita K, Hasegawa S, et al. Gene expression analysis by cDNA microarray in oral squamous cell carcinoma. J Oral Pathol Med 2006; 35: 206-11.
53. Raju B, Hultstrom M, Haug SR, et al. Sympathectomy suppresses tumor growth and alters gene-expression profiles in rat tongue cancer. Eur J Oral Sci 2009; 117: 351-61.
54. Tada T. The immune system as a supersystem. Annu Rev Immunol 1997; 15: 1-13.
55. Madden KS, Sanders VM, Felten DL. Catecholamine influences and sympathetic neural modulation of immune responsiveness. Annu Rev Pharmacol Toxicol 1995; 35: 417-48.
56. Elenkov IJ, Wilder RL, Chrousos GP, et al. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000; 52: 595-638.
57. Lundberg JM, Terenius L, Hokfelt T, et al. High levels of neuropeptide Y in peripheral noradrenergic neurons in various mammals including man. Neurosci Lett 1983; 42: 167-72.
58. Breivik T, Gundersen Y, Opstad PK, et al. Chemical sympathectomy inhibits periodontal disease in Fischer 344 rats. J Periodontal Res 2005; 40: 325-30.
59. Chibuzo GA, Cummings JF, Evans HE. Autonomic innervation of the tongue: a horseradish peroxidase study in the dog. J Auton Nerv Syst 1980; 2: 117-29.
60. Coderre TJ, Basbaum AI, Levine JD. Neural control of vascular permeability: interactions between primary afferents, mast cells, and sympathetic efferents. J Neurophysiol 1989; 62: 48-58.
61. Erici I, Folkow B, Uvnas B. Sympathetic vasodilator nerves to the tongue of the cat. Acta Physiol Scand 1952; 25: 1-9.
62. Wang HW, Chiou WY. Sympathetic innervation of the tongue in rats. ORL J Otorhinolaryngol Relat Spec 2004; 66: 16-20.
63. Ito J, Oyagi S. Determination of the origin of autonomic nerves of the tongue using horseradish peroxidase as tracer. Eur Arch Otorhinolaryngol 1994; 251: 117-8.
64. Pohto P, Antila R, Klinge E. Quantitation of transmitter noradrenaline in the pulps of cat canine teeth. Proc Finn Dent Soc 1972; 68: 20-5.
65. Matthews B, Robinson PP. The course of post-ganglionic sympathetic fibres distributed with the trigeminal nerve in the cat. J Physiol 1980; 303: 391-401.
66. Pleschka K. Control of tongue blood flow in regulation of heat loss in mammals. Rev Physiol Biochem Pharmacol 1984; 100: 75-120.
67. Norevall L, Forsgren S. NPY/sympathetic and NPY/VIP innervation of the blood vessels supplying rat tooth-related structures: effects of sympathectomy. Neuropeptides 1999; 33: 216-26.
68. Haug SR, Berggreen E, Heyeraas KJ. The effect of unilateral sympathectomy and cavity preparation on peptidergic nerves and immune cells in rat dental pulp. Exp Neurol 2001; 169: 182-90.
69. Uddman R, Grunditz T, Sundler F. Neuropeptide Y: occurrence and distribution in dental pulps. Acta Odontol Scand 1984; 42: 361-5.
70. Raju B, Haug SR, Ibrahim SO, et al. Sympathectomy decreases size and invasiveness of tongue cancer in rats. Neuroscience 2007; 149: 715-25.
71. Felten DL, Felten SY, Carlson SL, et al. Noradrenergic and peptidergic innervation of lymphoid tissue. J Immunol 1985; 135: 755s-65s.
72. Madden KS. Catecholamines, sympathetic innervation, and immunity. Brain Behav Immun 2003; 1: S5-10.
73. Madden KS, Felten DL. Experimental basis for neural-immune interactions. Physiol Rev 1995; 75: 77-106.
74. Friedman EM, Irwin MR. Modulation of immune cell function by the autonomic nervous system. Pharmacol Ther 1997; 74: 27-38.
75. Bracci-Laudiero L, Aloe L, Stenfors C, et al. Nerve growth factor stimulates production of neuropeptide Y in human lymphocytes. Neuroreport 1996; 7: 485-8.
76. Flierl MA, Rittirsch D, Huber-Lang M, et al. Catecholamines-crafty weapons in the inflammatory arsenal of immune/inflammatory cells or opening pandora's box? Mol Med 2008; 14: 195-204.
77. Josefsson E, Bergquist J, Ekman R, et al. Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis. Immunology 1996; 88: 140-6.
78. Frohman EM, Monson NL, Lovett-Racke AE, et al. Autonomic regulation of neuroimmunological responses: implications for multiple sclerosis. J Clin Immunol 2001; 21: 61-73.
79. Entschladen F, Palm D, Lang K, et al. Neoneurogenesis: tumors may initiate their own innervation by the release of neurotrophic factors in analogy to lymphangiogenesis and neoangiogenesis. Med Hypotheses 2006; 67: 33-5.
80. Schuller HM. Neurotransmission and cancer: implications for prevention and therapy. Anticancer Drugs 2008; 19: 655-71.
81. Shang ZJ, Liu K, Liang de F. Expression of beta2-adrenergic receptor in oral squamous cell carcinoma. J Oral Pathol Med 2009; 38: 371-6.
82. Luthy IA, Bruzzone A, Pinero CP, et al. Adrenoceptors: non conventional target for breast cancer? Curr Med Chem 2009; 16: 1850-62.
83. Drell TLT, Joseph J, Lang K, et al. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 2003; 80: 63-70.
84. Lutgendorf SK, Cole S, Costanzo E, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 2003; 9: 4514-21.
85. Yang EV, Sood AK, Chen M, et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006; 66: 10357-64.
86. Zhang H, Faber JE. Trophic effect of norepinephrine on arterial intima-media and adventitia is augmented by injury and mediated by different alpha1-adrenoceptor subtypes. Circ Res 2001; 89: 815-22.
87. Zhang H, Chalothorn D, Jackson LF, et al. Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle. Circ Res 2004; 95: 989-97.
88. Lee EW, Michalkiewicz M, Kitlinska J, et al. Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest 2003; 111: 1853-62.
89. Kishimoto K, Sasaki A, Yoshihama Y, et al. Expression of vascular endothelial growth factor-C predicts regional lymph node metastasis in early oral squamous cell carcinoma. Oral Oncol 2003; 39: 391-6.
90. Korner M, Reubi JC. NPY receptors in human cancer: a review of current knowledge. Peptides 2007; 28: 419-25.
91. Ruscica M, Dozio E, Motta M, et al. Relevance of the neuropeptide Y system in the biology of cancer progression. Curr Top Med Chem 2007; 7: 1682-91.
92. Entschladen F, Lang K, Drell TL, et al. Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol Immunother 2002; 51: 467-82.
93. Joon Yun A, Bazar KA, Lee PY. Tumors may modulate host immunity partly through hypoxia-induced sympathetic bias. Med Hypotheses 2004; 63: 352-6.
94. Adams DO. Molecular biology of macrophage activation: a pathway whereby psychosocial factors can potentially affect health. Psychosom Med 1994; 56: 316-27.
95. Ben-Eliyahu S, Shakhar G, Page GG, et al. Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoceptors. Neuroimmunomodulation 2000; 8: 154-64.
96. Felten SY, Madden KS, Bellinger DL, et al. The role of the sympathetic nervous system in the modulation of immune responses. Adv Pharmacol 1998; 42: 583-7.
97. Kurimoto N, Nan YS, Chen ZY, et al. Effects of specific signal transduction inhibitors on increased permeability across rat endothelial monolayers induced by neuropeptide Y or VEGF. Am J Physiol Heart Circ Physiol 2004; 287: H100-6.
98. Kitlinska J, Abe K, Kuo L, et al. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res 2005; 65: 1719-28.
99. Howarth D, Burstal R, Hayes C, et al. Autonomic regulation of lymphatic flow in the lower extremity demonstrated on lymphoscintigraphy in patients with reflex sympathetic dystrophy. Clin Nucl Med 1999; 24: 383-7.
100. Al-Wadei HA, Al-Wadei MH, Schuller HM. Prevention of pancreatic cancer by the beta-blocker propranolol. Anticancer Drugs 2009; 20: 477-82.
101. Park PG, Merryman J, Orloff M, et al. Beta-adrenergic mitogenic signal transduction in peripheral lung adenocarcinoma: implications for individuals with preexisting chronic lung disease. Cancer Res 1995; 55: 3504-8.
102. Shen SG, Zhang D, Hu HT, et al. Effects of alpha-adrenoreceptor antagonists on apoptosis and proliferation of pancreatic cancer cells in vitro. World J Gastroenterol 2008; 14: 2358-63.
103. Kyprianou N, Chon J, Benning CM. Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease. Prostate Suppl 2000; 9: 42-6.
104. Harris AM, Warner BW, Wilson JM, et al. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol 2007; 178: 2176-80.
105. Algazi M, Plu-Bureau G, Flahault A, et al. [Could treatments with beta-blockers be associated with a reduction in cancer risk?]. Rev Epidemiol Sante Publique 2004; 52: 53-65.
106. Kribben A, Wieder Ed, Li X, et al. AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C. Am J Physiol 1993; 265: C939-45.
107. Zeng C, Zhou Y, Liu G, et al. The signal transduction pathway causing the synergistic hypertrophic effects of neuropeptide Y and norepinephrine on primary cardiomyocyte. Neuropeptides 2001; 35: 211-8.
108. Thaker PH, Lutgendorf SK, Sood AK. The neuroendocrine impact of chronic stress on cancer. Cell Cycle 2007; 6: 430-3.
109. Kimura M, Okamoto H, Ogihara M. Activation of mitogen-activated protein kinase by hepatocyte growth factor is stimulated by both alpha1- and beta2-adrenergic agonists in primary cultures of adult rat hepatocytes. J Pharmacol Sci 2007; 103: 398-407.
110. Wan Y, Huang XY. Analysis of the Gs/mitogen-activated protein kinase pathway in mutant S49 cells. J Biol Chem 1998; 273: 14533-7.
111. Haug SR, Heyeraas KJ. Modulation of dental inflammation by the sympathetic nervous system. J Dent Res 2006; 85: 488-95.
112. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
113. Grzanna R, Frondoza CG, Otten U. Sympathectomy inhibits growth of a murine plasmacytoma tumor. J Auton Nerv Syst 1985; 13: 149-60.
114. Innominato PF, Libbrecht L, Van den Oord JJ. Expression of neurotrophins and their receptors in pigment cell lesions of the skin. J Pathol 2001; 194: 95-100.